Compare BLFS & HYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLFS | HYT |
|---|---|---|
| Founded | 1987 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2013 | N/A |
| Metric | BLFS | HYT |
|---|---|---|
| Price | $26.01 | $8.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $32.00 | N/A |
| AVG Volume (30 Days) | ★ 734.8K | 689.0K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.61% |
| EPS Growth | ★ 77.27 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $96,214,000.00 | N/A |
| Revenue This Year | $19.73 | N/A |
| Revenue Next Year | $17.82 | N/A |
| P/E Ratio | $1,276.50 | ★ N/A |
| Revenue Growth | ★ 16.97 | N/A |
| 52 Week Low | $17.86 | $8.22 |
| 52 Week High | $29.57 | $9.88 |
| Indicator | BLFS | HYT |
|---|---|---|
| Relative Strength Index (RSI) | 55.48 | 40.85 |
| Support Level | $23.60 | $8.38 |
| Resistance Level | $26.59 | $8.70 |
| Average True Range (ATR) | 1.41 | 0.06 |
| MACD | -0.24 | -0.01 |
| Stochastic Oscillator | 41.06 | 2.78 |
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
BlackRock Corporate High Yield Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is to provide shareholders with current income. The trust's secondary investment objective is to provide shareholders with capital appreciation. Under Normal market conditions, the fund invests at least 80% of its net assets in high-yield securities of corporate issuers and derivatives that provide exposure to those securities or related market risk factors.